Larimar Therapeutics Inc (LRMR)
7.43
-0.44
(-5.59%)
USD |
NASDAQ |
May 16, 16:00
7.43
0.00 (0.00%)
After-Hours: 20:00
Larimar Therapeutics Enterprise Value: 246.75M for May 16, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 16, 2024 | 246.75M |
| May 15, 2024 | 274.83M |
| May 14, 2024 | 275.46M |
| May 13, 2024 | 239.73M |
| May 10, 2024 | 226.97M |
| May 09, 2024 | 274.19M |
| May 08, 2024 | 278.02M |
| May 07, 2024 | 291.41M |
| May 06, 2024 | 298.42M |
| May 03, 2024 | 268.11M |
| May 02, 2024 | 258.22M |
| May 01, 2024 | 241.63M |
| April 30, 2024 | 212.29M |
| April 29, 2024 | 194.42M |
| April 26, 2024 | 183.58M |
| April 25, 2024 | 176.56M |
| April 24, 2024 | 184.85M |
| April 23, 2024 | 184.85M |
| April 22, 2024 | 181.02M |
| April 19, 2024 | 189.32M |
| April 18, 2024 | 179.75M |
| April 17, 2024 | 222.49M |
| April 16, 2024 | 234.62M |
| April 15, 2024 | 238.44M |
| April 12, 2024 | 216.75M |
| Date | Value |
|---|---|
| April 11, 2024 | 233.34M |
| April 10, 2024 | 209.10M |
| April 09, 2024 | 221.86M |
| April 08, 2024 | 233.34M |
| April 05, 2024 | 247.38M |
| April 04, 2024 | 236.53M |
| April 03, 2024 | 265.24M |
| April 02, 2024 | 242.27M |
| April 01, 2024 | 248.65M |
| March 28, 2024 | 397.45M |
| March 27, 2024 | 376.72M |
| March 26, 2024 | 372.57M |
| March 25, 2024 | 396.81M |
| March 22, 2024 | 429.35M |
| March 21, 2024 | 459.34M |
| March 20, 2024 | 457.42M |
| March 19, 2024 | 461.25M |
| March 18, 2024 | 445.94M |
| March 15, 2024 | 468.27M |
| March 14, 2024 | 467.95M |
| March 13, 2024 | 506.55M |
| March 12, 2024 | 472.74M |
| March 11, 2024 | 462.47M |
| March 08, 2024 | 562.40M |
| March 07, 2024 | 608.22M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-28.91M
Minimum
Jun 17 2022
726.60M
Maximum
Feb 16 2024
108.04M
Average
87.75M
Median
Dec 14 2021
Enterprise Value Benchmarks
| Cogent Biosciences Inc | 524.55M |
| ACADIA Pharmaceuticals Inc | 2.028B |
| PTC Therapeutics Inc | 1.981B |
| Renovaro Inc | 142.36M |
| G1 Therapeutics Inc | 223.11M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -14.65M |
| Total Expenses (Quarterly) | 16.73M |
| EPS Diluted (Quarterly) | -0.27 |
| Earnings Yield | -12.92% |